Financials Alamar Biosciences, Inc.
Stocks
ALMR
US0109111056
Advanced Medical Equipment & Technology
|
Real-time Estimate
Cboe BZX
10:56:15 2026-10-01 EDT
|
5-day change | 1st Jan Change | ||
| 34.44 USD | +1.07% |
|
+2.21% | - |
Projected Income Statement: Alamar Biosciences, Inc.
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Net sales 1 | - | 118.6 | 165.7 | 224.2 |
| Change | - | - | 39.75% | 35.28% |
| EBITDA 1 | - | -54.44 | -44.84 | -18.3 |
| Change | - | - | 17.64% | 59.18% |
| EBIT 1 | - | -58.86 | -50.31 | -23.63 |
| Change | - | - | 14.53% | 53.02% |
| Interest Paid 1 | - | -0.2 | - | - |
| Earnings before Tax (EBT) 1 | - | -61.8 | -38.75 | -14.5 |
| Change | - | - | 37.3% | 62.58% |
| Net income 1 | -29.82 | -64.94 | -49.86 | -25.39 |
| Change | - | -117.78% | 23.22% | 49.09% |
| Announcement Date | 3/12/26 | - | - | - |
1USD in Million
Estimates
Forecast Balance Sheet: Alamar Biosciences, Inc.
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| Net Debt 1 | - | -188 | -156 | -125 |
| Change | - | - | 17.02% | 19.87% |
| Announcement Date | 3/12/26 | - | - | - |
1USD in Million
Estimates
Cash Flow Forecast: Alamar Biosciences, Inc.
| Fiscal Period: December | 2026 | 2027 | 2028 |
|---|---|---|---|
| CAPEX 1 | 11 | 5.933 | 4.667 |
| Change | - | -46.06% | -21.35% |
| Free Cash Flow (FCF) 1 | -81 | -48.9 | -23.25 |
| Change | - | 39.63% | 52.45% |
| Announcement Date | - | - | - |
1USD in Million
Estimates
Forecast Financial Ratios: Alamar Biosciences, Inc.
| Fiscal Period: December | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
Profitability | ||||
| EBITDA Margin (%) | - | -45.91% | -27.06% | -8.16% |
| EBIT Margin (%) | - | -49.64% | -30.36% | -10.54% |
| EBT Margin (%) | - | -52.12% | -23.38% | -6.47% |
| Net margin (%) | - | -54.77% | -30.09% | -11.32% |
| FCF margin (%) | - | -68.31% | -29.51% | -10.37% |
| FCF / Net Income (%) | - | 124.73% | 98.07% | 91.59% |
Profitability | ||||
| ROA | - | -28.06% | -12.57% | -9.11% |
| ROE | - | -88.11% | -21.22% | -15.74% |
Financial Health | ||||
| Leverage (Debt/EBITDA) | - | - | - | - |
| Debt / Free cash flow | - | - | - | - |
Capital Intensity | ||||
| CAPEX / Current Assets (%) | - | 9.28% | 3.58% | 2.08% |
| CAPEX / EBITDA (%) | - | -20.21% | -13.23% | -25.5% |
| CAPEX / FCF (%) | - | -13.58% | -12.13% | -20.07% |
Items per share | ||||
| Cash flow per share 1 | - | -1.288 | -0.9947 | - |
| Change | - | - | 22.75% | - |
| Dividend per Share 1 | - | - | - | - |
| Change | - | - | - | - |
| Book Value Per Share 1 | - | 3.835 | 2.665 | 2.617 |
| Change | - | - | -30.52% | -1.79% |
| EPS 1 | -6.256 | -1.216 | -0.6924 | -0.3553 |
| Change | - | 80.55% | 43.08% | 48.69% |
| Nbr of stocks (in thousands) | - | 69,393 | 69,393 | 69,393 |
| Announcement Date | 3/12/26 | - | - | - |
1USD
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | -28x | -49.2x |
| PBR | 8.88x | 12.8x |
| EV / Sales | 18.4x | 13.3x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Year-on-year evolution of the Yield
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
34.07USD
Average target price
35.40USD
Spread / Average Target
+3.90%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALMR Stock
- Financials Alamar Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
